Swedish Orphan Biovitrum AB (publ) (Sobi), an international specialty healthcare company, announced that the company has gained commercial rights from the Swiss based company PharmaSwiss SA, to distribute Relistor, Deflux and Solesta in a territory including Western Europe, Czech Republic, Slovakia, Hungary and also for Relistor in Russia.

"I am delighted that we have expanded our successful partnership with PharmaSwiss and provide patients and physicians with additional treatment options that address unmet medical needs in each specific therapeutic category," said Alan Raffensperger, senior vice president and chief operating officer at Sobi.

Sobi will handle all commercial activities in the territory including launch, market and patient access and promotion activities, while PharmaSwiss will be responsible for manufacturing, providing the finished products and products' information.

The three new products that Sobi will distribute, one pharmaceutical and two medical devices, are all approved for specialty care indications:

Relistor (methylnaltrexone bromide) is indicated for treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older;

Deflux is indicated for treatment of children with vesicoureteral reflux;

Solesta is indicated for the treatment of faecal incontinence in patients 18 years and older who have failed conservative therapy.

In June 2013, Sobi announced its first distribution agreement with PharmaSwiss to market the products Megace, Monopril, Cefzil and Duricef approved for the treatment of indications within the oncology, cardio-vascular and anti-infective therapy areas.